Tesaro (Boston, MA) a clinical-stage biopharmaceutical focused on chemotherapy induced nausea and non-small cell lung cancer, closed a $101M Series B financing. Participants include New Enterprise Associates, InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Capital Management and Leerink Swann.